文献速递甲状腺核医学肿瘤 PET/CT

双时间点[18F]氟吡啶嗪PET/CT定位原发性甲状旁腺功能亢进症甲状旁腺腺瘤的初步经验

Initial Experience with Dual-Time-Point [18F]Flurpiridaz PET/CT for Localization of Parathyroid Adenomas in Primary Hyperparathyroidism.
PubMed 文献 · J Nucl Med · 2025-06-02

回顾性分析11例原发性甲状旁腺功能亢进症患者,评估双时间点[18F]氟吡啶嗪PET/CT定位甲状旁腺腺瘤的可行性。PET/CT在10例(91%)中识别出甲状旁腺腺瘤,腺瘤仅在早期PET图像中显影。腺瘤摄取值随时间下降(SUVmax -65% ± 17%;P = 0.002),背景甲状腺组织摄取值亦下降(-56% ± 16%;P = 0.002)。结论认为给药后[18F]氟吡啶嗪PET图像在pHPT中具有高检出效能,为更大规模前瞻性研究提供依据。

要点

  • 11例pHPT患者中,[18F]氟吡啶嗪PET/CT识别出10例(91%)甲状旁腺腺瘤。
  • 甲状旁腺腺瘤仅在早期PET图像中显影。
  • 腺瘤SUVmax随时间下降65% ± 17%(P = 0.002),背景甲状腺组织下降56% ± 16%(P = 0.002)。

核心结论

  • 给药后[18F]氟吡啶嗪PET图像在原发性甲状旁腺功能亢进症中具有高检出效能。
  • 本研究为更大规模前瞻性研究评估[18F]氟吡啶嗪PET/CT定位功能亢进甲状旁腺与其他影像检查的比较提供了依据。

研究设计与样本

  • 回顾性分析11例原发性甲状旁腺功能亢进症患者,均接受双时间点[18F]氟吡啶嗪PET/CT定位功能亢进的甲状旁腺。
  • PET/CT findings与其它影像检查、实验室参数、术中所见及最终组织学比较,并以最终组织学为参考标准。

主要发现

  • [18F]氟吡啶嗪PET/CT在11例受检患者中识别出10例(91%)甲状旁腺腺瘤。
  • 甲状旁腺腺瘤仅在早期PET图像中显影。
  • 腺瘤摄取值随时间下降:SUVmax变化-65% ± 17%(P = 0.002)。
  • 背景甲状腺组织摄取值随时间下降:-56% ± 16%(P = 0.002)。

局限性

  • 本研究为回顾性分析。
  • 样本量为11例患者。
  • 作者指出需要更大规模前瞻性研究来评估[18F]氟吡啶嗪PET/CT定位功能亢进甲状旁腺与其他影像检查的比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We aimed to evaluate the feasibility of [18F]flurpiridaz PET/CT for localization of parathyroid adenomas in patients with primary hyperparathyroidism (pHPT). Methods: Data for 11 patients with pHPT undergoing dual-time-point [18F]flurpiridaz PET/CT for localization of hyperfunctioning parathyroid glands were retrospectively analyzed. PET/CT findings were compared with results of other imaging tests, laboratory parameters, intraoperative findings, and final histology, serving as the reference standard. Results: [18F]flurpiridaz PET/CT identified parathyroid adenomas in 10 (91%) of the 11 patients studied. Parathyroid adenomas were exclusively visualized in early PET images. Uptake in adenomas declined over time (SUVmax, -65% ± 17%; P = 0.002), as did uptake in background thyroid tissue (-56% ± 16%; P = 0.002). Conclusion: [18F]flurpiridaz PET images after administration had high detection efficacy in pHPT. This work provides a rationale for larger prospective studies to evaluate the use of [18F]flurpiridaz PET/CT for localization of hyperfunctioning parathyroid glands in comparison with other imaging tests.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Derlin T, Kleine-Döpke D, Neubert L, et al. Initial Experience with Dual-Time-Point [18F]Flurpiridaz PET/CT for Localization of Parathyroid Adenomas in Primary Hyperparathyroidism. J Nucl Med. 2025. PMID: 40274375. doi:10.2967/jnumed.124.269387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。